Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press8810.17650/1994-4098-2012-0-1-102-112GYNECOLOGY. TREATMENTГИНЕКОЛОГИЯ. ЛЕЧЕНИЕThe leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancerВедущая роль топотекана в лечении платинорезистентных рецидивов рака яичниковBorisovK. E.БорисовК. Е.
Russian Federation
konstantin9671@rambler.ruBashkirsky State Medical UniversityБашкирский государственный медицинский университет23022012110211223072014230720142012https://ojrs.abvpress.ru/ojrs/article/view/88

The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is recommended weekly injection of 4 mg/m2 in 1, 8, 15 days of a 28-day cycle of therapy, as its effectiveness is comparable to the effectiveness of the standard 5-day regime.

В обзоре представлены данные об эффективности применения ингибитора топоизомеразы I топотекана у больных с рецидивами рака яичников в сравнении с другими химиотерапевтическими агентами. Показано, что топотекан может быть препаратом выбора при платинорезистентных рецидивах. Для уменьшения степени гематологической токсичности рекомендовано ежене- дельное введение препарата в дозе 4 мг/м2 в 1, 8, 15-й дни 28-дневного цикла терапии, эффективность которого сопоставима с эффективностью стандартного 5-дневного режима.

ovarian cancerrecurrenceplatinum-free intervaltopotecanweekly regimenрак яичниковрецидивбесплатиновый интервалтопотеканеженедельное введение1. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Под ред. М.И. Давыдова и Е.М. Аксель. Вестн РОНЦ им. Н.Н. Блохина РАМН 2011;22(3).Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Под ред. М.И. Давыдова и Е.М. Аксель. Вестн РОНЦ им. Н.Н. Блохина РАМН 2011;22(3).2. Bookman M.A., Brady M.F., McGuire W.P. et al. Evaluation of new platinum-based treatment regiments in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J Clin Oncol 2009; 27(9):1419−25.Bookman M.A., Brady M.F., McGuire W.P. et al. Evaluation of new platinum-based treatment regiments in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J Clin Oncol 2009; 27(9):1419−25.3. Bookman M.A. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The Oncologist 1999;4(2):87−94.Bookman M.A. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The Oncologist 1999;4(2):87−94.4. Kingsbury W.D., Boehm J.C., Jakas D.R. et al. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991;(34):98−107.Kingsbury W.D., Boehm J.C., Jakas D.R. et al. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991;(34):98−107.5. Del Bino G., Lassota P., Darzynkiewisz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res 1991;(193):27−35.Del Bino G., Lassota P., Darzynkiewisz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res 1991;(193):27−35.6. Kudelka A.P., Tresukosol D., Edwards C.L. et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14(5):1552−7.Kudelka A.P., Tresukosol D., Edwards C.L. et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14(5):1552−7.7. Creemers G.J., Bolis G., Gore M. et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14(12):3056−61.Creemers G.J., Bolis G., Gore M. et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14(12):3056−61.8. Swisher E.M., Mutch D.G., Rades J.S. et al. Topotecan in platinum- and paclitaxel- resistant ovarian cancer. Gynecol Oncol 1997;66(3):480−6.Swisher E.M., Mutch D.G., Rades J.S. et al. Topotecan in platinum- and paclitaxel- resistant ovarian cancer. Gynecol Oncol 1997;66(3):480−6.9. Bookman M.A., Malmstrom H., Bolis G. et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16(10):3345−52.Bookman M.A., Malmstrom H., Bolis G. et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16(10):3345−52.10. Hoskins P., Eisenhauer E., Beare S. et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16(6):2233−7.Hoskins P., Eisenhauer E., Beare S. et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16(6):2233−7.11. McGuire W.P., Blessing J.A., Bookman M.A. et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2000; 18(5):1062−7.McGuire W.P., Blessing J.A., Bookman M.A. et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2000; 18(5):1062−7.12. Malik I.A. An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer — single institution experience in a developing country. Int J Gynecol Cancer 2000;10(6):443−8.Malik I.A. An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer — single institution experience in a developing country. Int J Gynecol Cancer 2000;10(6):443−8.13. Li J.D., Guan Z.Z., Liu J.H. et al. Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer. Ai Zheng 2002;21(4):416−20.Li J.D., Guan Z.Z., Liu J.H. et al. Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer. Ai Zheng 2002;21(4):416−20.14. Beshara N., Fung Kee Fung M., Faught W. The role of topotecan as second-line therapy in patients with recurrent ovarian cancer. Eur J Gynecol Oncol 2002;23(4):287−90.Beshara N., Fung Kee Fung M., Faught W. The role of topotecan as second-line therapy in patients with recurrent ovarian cancer. Eur J Gynecol Oncol 2002;23(4):287−90.15. Karabulut B., Sezgin C., Terec M.C. et al. Topotecan in platinum-resistant epithelial ovarian cancer. Chemotherapy 2005; 51(6):347−51.Karabulut B., Sezgin C., Terec M.C. et al. Topotecan in platinum-resistant epithelial ovarian cancer. Chemotherapy 2005; 51(6):347−51.16. Ten Bokkel Huinink W., Gore M., Carmichael J. et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15(6):2183−93.Ten Bokkel Huinink W., Gore M., Carmichael J. et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15(6):2183−93.17. Ten Bokkel Huinink W., Lane S.R., Ross G.A. Long-term survival in a phase III, randomized study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004;15(1):100−3.Ten Bokkel Huinink W., Lane S.R., Ross G.A. Long-term survival in a phase III, randomized study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004;15(1):100−3.18. Gore M., Ten Bokkel Huinink W., Carmichael J. et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 2001; 19(7):1893−900.Gore M., Ten Bokkel Huinink W., Carmichael J. et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 2001; 19(7):1893−900.19. Gordon A.N., Fleagle J.T., Guthrie D. et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19(14):3312−22.Gordon A.N., Fleagle J.T., Guthrie D. et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19(14):3312−22.20. Gordon A.N., Tonda M., Sun S., Rackoff W. Doxil Study 39−40 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomised study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1−8.Gordon A.N., Tonda M., Sun S., Rackoff W. Doxil Study 39−40 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomised study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1−8.21. Dupont J., Aghajanian C., Andrea G. et al. Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important? Int J Gynecol Cancer 2006; 16(Suppl 1):68−73.Dupont J., Aghajanian C., Andrea G. et al. Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important? Int J Gynecol Cancer 2006; 16(Suppl 1):68−73.22. Meier W., du Bois A., Reuss A. et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy.Meier W., du Bois A., Reuss A. et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy.A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol.Oncol 2009; 114(2):199−205.23. Prasad M., Ben-Porat L., Hoppe B. et al. Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynecol Oncol 2004;93(1):223−8.Prasad M., Ben-Porat L., Hoppe B. et al. Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynecol Oncol 2004;93(1):223−8.24. Armstrong D.K., Spriggs D., Levin J. et al. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist 2005;10(9):686−94.Armstrong D.K., Spriggs D., Levin J. et al. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist 2005;10(9):686−94.25. Goldwasser F., Buthaud X., Gross M. et al. Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anticancer Drugs 1999;10(3):263−5.Goldwasser F., Buthaud X., Gross M. et al. Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anticancer Drugs 1999;10(3):263−5.26. Cormio G., Loizzi V., Gissi F. et al. Long-term topotecan therapy in recurrent or persistent ovarian cancer. Eur J Gynaecol Oncol 2011;32(2):153−5.Cormio G., Loizzi V., Gissi F. et al. Long-term topotecan therapy in recurrent or persistent ovarian cancer. Eur J Gynaecol Oncol 2011;32(2):153−5.27. Mobus V., Kieback D.G., Kaubitzsch S.K. Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis. Anticancer Res 2007; 27(3):1581−7.Mobus V., Kieback D.G., Kaubitzsch S.K. Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis. Anticancer Res 2007; 27(3):1581−7.28. Aravantinos G., Zafiropoulos A., Bafaloukos D. et al. Topotecan in heavily pretreated platinum resistant ovarian cancer patients. 10th Symposium of New Drugs in Cancer Therapy. Amsterdam, 1998. Abstr 67.Aravantinos G., Zafiropoulos A., Bafaloukos D. et al. Topotecan in heavily pretreated platinum resistant ovarian cancer patients. 10th Symposium of New Drugs in Cancer Therapy. Amsterdam, 1998. Abstr 67.29. Nielsen H.A., Nielsen D., Engelholm S.A. Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer. Gynecol Oncol 2000;77:383−8.Nielsen H.A., Nielsen D., Engelholm S.A. Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer. Gynecol Oncol 2000;77:383−8.30. Rodriguez M., Rose P.G. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001;83:257−62.Rodriguez M., Rose P.G. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001;83:257−62.31. Gronlund B., Hansen H.H., Høgdall C., Engelholm S.A. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer 2002;95(8):1656−62.Gronlund B., Hansen H.H., Høgdall C., Engelholm S.A. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer 2002;95(8):1656−62.32. Piura B., Rabinovich A. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma. Int J Gynecol Cancer 2005; 15(4):612−7.Piura B., Rabinovich A. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma. Int J Gynecol Cancer 2005; 15(4):612−7.33. Mitchell S.K., Carson L.F., Judson P., Downs L.S. Jr. Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review. Int J Gynecol Cancer 2005;15(5):793−8.Mitchell S.K., Carson L.F., Judson P., Downs L.S. Jr. Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review. Int J Gynecol Cancer 2005;15(5):793−8.34. Brown 3rd J.V., Peters 3rd W.A., Rettenmaier M.A. et al. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecol Oncol 2000; 79:495−8.Brown 3rd J.V., Peters 3rd W.A., Rettenmaier M.A. et al. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecol Oncol 2000; 79:495−8.35. Markman M., Kennedy A., Webster K. et al. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel- refractory ovarian cancer. Gynecol Oncol 2000;79:116−9.Markman M., Kennedy A., Webster K. et al. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel- refractory ovarian cancer. Gynecol Oncol 2000;79:116−9.36. Miller D.S., Blessing J.A., Lentz S.S., McMeekin D.S. Phase II evaluation of three- day topotecan in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 2003;98(98):1664−9.Miller D.S., Blessing J.A., Lentz S.S., McMeekin D.S. Phase II evaluation of three- day topotecan in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 2003;98(98):1664−9.37. Brown J.V. 3rd, Peters W.A. 3rd, Rettenmaier M.A. et al. Three-consecutive- day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol 2003;88(2):136−40.Brown J.V. 3rd, Peters W.A. 3rd, Rettenmaier M.A. et al. Three-consecutive- day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol 2003;88(2):136−40.38. Herzog T.J., Powell M.A., Rader J.S. et al. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol 2006;103(2):637−41.Herzog T.J., Powell M.A., Rader J.S. et al. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol 2006;103(2):637−41.39. Calcagno M., Bellati F., Palaia I. et al. Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients. Int J Gynecol Cancer 2009;19(3):455−9.Calcagno M., Bellati F., Palaia I. et al. Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients. Int J Gynecol Cancer 2009;19(3):455−9.40. Hochster H., Wadler S., Runowicz C. et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol 1999; 17(8):2553−61.Hochster H., Wadler S., Runowicz C. et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol 1999; 17(8):2553−61.41. Gore M., Rustin G., Schüller J. et al. Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. Br J Cancer 2001;84(8):1043−6.Gore M., Rustin G., Schüller J. et al. Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. Br J Cancer 2001;84(8):1043−6.42. Denschlag D., Watermann D., Horig K. et al. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients. Anticancer Res 2004;24(2):1267−9.Denschlag D., Watermann D., Horig K. et al. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients. Anticancer Res 2004;24(2):1267−9.43. Elcas J.C., Holschneider C.H., Katz B. et al. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. Int J Gynecol Cancer 2003;13(2):138−41.Elcas J.C., Holschneider C.H., Katz B. et al. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. Int J Gynecol Cancer 2003;13(2):138−41.44. Rose P.G., Gordon N.H., Fusco N. et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant ovarian carcinoma. Gynecol Oncol 2000;78(2):228−34.Rose P.G., Gordon N.H., Fusco N. et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant ovarian carcinoma. Gynecol Oncol 2000;78(2):228−34.45. Markman M., Blessing J.A., Alvarez R.D. et al. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2000;77(1):112−5.Markman M., Blessing J.A., Alvarez R.D. et al. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2000;77(1):112−5.46. Markman M., Blessing J.A., DeGeest K. et al. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial. Gynecol Oncol 1999;75(3):444−6.Markman M., Blessing J.A., DeGeest K. et al. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial. Gynecol Oncol 1999;75(3):444−6.47. Homesley H.D., Hall D.J., Martin D.A. et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001;83(2):394−9.Homesley H.D., Hall D.J., Martin D.A. et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001;83(2):394−9.48. Bhoola S.M., Coleman R.L., Herzog T. et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 2004; 95(3):564−9.Bhoola S.M., Coleman R.L., Herzog T. et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 2004; 95(3):564−9.49. Largillier R., Valenza B., Ferrero J.M. et al. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum- based therapy. Oncology 2007;73(3−4):177−84.Largillier R., Valenza B., Ferrero J.M. et al. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum- based therapy. Oncology 2007;73(3−4):177−84.50. Le T., Hopkins L., Baines K.A. et al. Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer. Int J Gynecol Cancer 2008;18(3):428−31.Le T., Hopkins L., Baines K.A. et al. Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer. Int J Gynecol Cancer 2008;18(3):428−31.51. Abushahin F., Singh D.K., Lurain J.R. et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol 2008;108(1):53−7.Abushahin F., Singh D.K., Lurain J.R. et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol 2008;108(1):53−7.52. Levy T., Inbar M., Menczer J. et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 2004;95(3):686−90.Levy T., Inbar M., Menczer J. et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 2004;95(3):686−90.53. O'Maley D.M., Azodi M., Makkenchery A. et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2005;98:242−8.O'Maley D.M., Azodi M., Makkenchery A. et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2005;98:242−8.54. Safra T., Menczer J., Bernstein R. et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol 2007;105(1):205−10.Safra T., Menczer J., Bernstein R. et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol 2007;105(1):205−10.55. Vandenput I., Amant F., Neven P. et al. Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. Int J Gynecol Oncol 2007;17(1):83−7.Vandenput I., Amant F., Neven P. et al. Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. Int J Gynecol Oncol 2007;17(1):83−7.56. Spannuth W.A., Leath C.A. 3rd, Huh W.K. et al. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol 2007;104(3):591−5.Spannuth W.A., Leath C.A. 3rd, Huh W.K. et al. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol 2007;104(3):591−5.57. Morris R., Alvarez R.D., Andrews S. et al. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol Oncol 2008;109(3):346−52.Morris R., Alvarez R.D., Andrews S. et al. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol Oncol 2008;109(3):346−52.58. Brown J.V.3rd, Rettenmaier M.A., Lopez K.L. et al. A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. Int J Gynecol Cancer 2008;18(2):249−54.Brown J.V.3rd, Rettenmaier M.A., Lopez K.L. et al. A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. Int J Gynecol Cancer 2008;18(2):249−54.59. Herzog T.J., Sill M.W., Walker J.L. et al. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol 2011;120(3):454−8.Herzog T.J., Sill M.W., Walker J.L. et al. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol 2011;120(3):454−8.60. Sehouli J., Stengel D., Harter P. et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2011;29(2):242−8.Sehouli J., Stengel D., Harter P. et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2011;29(2):242−8.61. Greggi S., Salerno M.G., D'Agostino G. et al. Topotecan and gemcitabine in platinum/ paclitaxel-resistant ovarian cancer. Oncology 2001;60(1):19−23.Greggi S., Salerno M.G., D'Agostino G. et al. Topotecan and gemcitabine in platinum/ paclitaxel-resistant ovarian cancer. Oncology 2001;60(1):19−23.62. Sehouli J., Stengel D., Oskay G. et al. Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum. Onkologie 2004;27(1):58−64.Sehouli J., Stengel D., Oskay G. et al. Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum. Onkologie 2004;27(1):58−64.63. Joly F., Petit T., Pautier P. et al. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study. Gynecol Oncol 2009;115(3):382−8.Joly F., Petit T., Pautier P. et al. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study. Gynecol Oncol 2009;115(3):382−8.64. Gupta D., Owers R.L., Kim M. et al. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancer. Gynecol Oncol 2009;113(3):327−30.Gupta D., Owers R.L., Kim M. et al. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancer. Gynecol Oncol 2009;113(3):327−30.65. Stathopoulos G.P., Malamos N.A., Aravantinos G. et al. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer Chemother Pharmacol 2007;60(1):123−8.Stathopoulos G.P., Malamos N.A., Aravantinos G. et al. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer Chemother Pharmacol 2007;60(1):123−8.66. Lortholary A., Largillier R., Weber B. et al. Weekly paclitaxel as single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol 2012;23(2):346−52.Lortholary A., Largillier R., Weber B. et al. Weekly paclitaxel as single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol 2012;23(2):346−52.67. Gramande S.A., Piver M.S. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum- resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study.Gramande S.A., Piver M.S. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum- resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study.J Surg Oncol 1999;72(3):162−6.68. Kang H., Kim T.J., Lee Y.Y. et al. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study. Gynecol Oncol 2009;114(2):210−4.Kang H., Kim T.J., Lee Y.Y. et al. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study. Gynecol Oncol 2009;114(2):210−4.69. Rose P.G., Monk B.J., Provencher D. et al. An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer. Gynecol Oncol 2011;120(1):38−42.Rose P.G., Monk B.J., Provencher D. et al. An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer. Gynecol Oncol 2011;120(1):38−42.70. Koensgen D., Stengel D., Belau A. et al. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of multicenter NOGGO: phase I/II study. Cancer Chemother.Pharmacol 2008; 62(3):393−400.Koensgen D., Stengel D., Belau A. et al. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of multicenter NOGGO: phase I/II study. Cancer Chemother.Pharmacol 2008; 62(3):393−400.71. Elkas J.C., Winter W.E. 3rd, Chernofsky M.R. et al. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. Gynecol Oncol 2007;104(2):422−7.Elkas J.C., Winter W.E. 3rd, Chernofsky M.R. et al. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. Gynecol Oncol 2007;104(2):422−7.72. Verhaar-Langereis M., Karakus A., van Eijkeren M. et al. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum- resistant ovarian cancer. Int J Gynecol Cancer 2006;16(1):65−70.Verhaar-Langereis M., Karakus A., van Eijkeren M. et al. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum- resistant ovarian cancer. Int J Gynecol Cancer 2006;16(1):65−70.73. Chiara S., Tognoni A., Pastrone I. et al. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecol Oncol 2004;93(2):474−8.Chiara S., Tognoni A., Pastrone I. et al. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecol Oncol 2004;93(2):474−8.74. Hanjani P., Nolte S., Shahin M.S. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecol Oncol 2002;85(2):278−84.Hanjani P., Nolte S., Shahin M.S. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecol Oncol 2002;85(2):278−84.75. Hochster H., Chen T.T., Lu J.M. et al. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treatad ovarian cancer. A phase I study. Gynecol Oncol 2008;108(3):500−4.Hochster H., Chen T.T., Lu J.M. et al. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treatad ovarian cancer. A phase I study. Gynecol Oncol 2008;108(3):500−4.76. Sehouli J., Stengel D., Oskay-Oezcelik G. et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2008; 261(19):3176−82.Sehouli J., Stengel D., Oskay-Oezcelik G. et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2008; 261(19):3176−82.77. Merrit W.M., Danes C.G., Shahzad M.M.K. et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 2009;8(16):1596−603.Merrit W.M., Danes C.G., Shahzad M.M.K. et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 2009;8(16):1596−603.78. Downs L.S. Jr., Judson P.L., Argenta P.A. et al. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 2008; 112(2):331−9.Downs L.S. Jr., Judson P.L., Argenta P.A. et al. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 2008; 112(2):331−9.79. McGonigle K.F., Muntz H.G., Vuky J. et al. Combined weekly topotecan and beweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 2011;117(16):3731−40.McGonigle K.F., Muntz H.G., Vuky J. et al. Combined weekly topotecan and beweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 2011;117(16):3731−40.80. Ramasubbaiah R., Perkins S.M., Schilder J. et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 2011;123(3):499−503.Ramasubbaiah R., Perkins S.M., Schilder J. et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 2011;123(3):499−503.81. Schwartzberg L.S., Stewart C.F., Schaiquevich P. et al. Phase I dosage-finding and pharmacokinetic (PK) study of intravenous topotecan and oral erlotinib in patients (pts) with refractory solid tumors.Schwartzberg L.S., Stewart C.F., Schaiquevich P. et al. Phase I dosage-finding and pharmacokinetic (PK) study of intravenous topotecan and oral erlotinib in patients (pts) with refractory solid tumors.J Clin Oncol 2008;20; аbstr 2549.82. Molina J.R., Kaufmann S.H., Reid J.M. et al. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res 2008;14(23):7900−8.Molina J.R., Kaufmann S.H., Reid J.M. et al. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res 2008;14(23):7900−8.83. Hashimoto K., Man S., Xu P. et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 2010;9(4):996−1006.Hashimoto K., Man S., Xu P. et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 2010;9(4):996−1006.